### Supplement 1:

**STROBE Checklist**

**STROBE Statement**—Checklist of items that should be included in reports of *cohort studies*

<table>
<thead>
<tr>
<th>Item No</th>
<th>Recommendation</th>
<th>Page located</th>
</tr>
</thead>
</table>
| **Title and abstract** | 1  
(a) Indicate the study’s design with a commonly used term in the title or the abstract  
(b) Provide in the abstract an informative and balanced summary of what was done and what was found | 2            |
| **Introduction** | 2  
Explain the scientific background and rationale for the investigation being reported | 4            |
| **Objectives** | 3  
State specific objectives, including any pre-specified hypotheses | 5            |
| **Methods** | 4  
Present key elements of study design early in the paper | 5            |
| **Setting** | 5  
Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 5            |
| **Participants** | 6  
(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up  
(b) For matched studies, give matching criteria and number of exposed and unexposed | 5 N/A        |
| **Variables** | 7  
Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 5-6          |
| **Data sources/measurement** | 8*  
For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 6            |
| **Bias** | 9  
Describe any efforts to address potential sources of bias | 5            |
| **Study size** | 10  
Explain how the study size was arrived at | 5, Figure 1  |
| **Quantitative variables** | 11  
Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 6            |
| **Statistical methods** | 12  
(a) Describe all statistical methods, including those used to control for confounding | 6            |
### Results

**Participants**
- **13***
  - (a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed
  - 7, Figure 1
  - (b) Give reasons for non-participation at each stage
  - 7, Figure 1
  - (c) Consider use of a flow diagram
  - Figure 1

**Descriptive data**
- **14***
  - (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders
  - 7-16, Table 1 & 2, Annex Table 1
  - (b) Indicate number of participants with missing data for each variable of interest
  - Tables 1 & 2
  - (c) Summarize follow-up time (e.g., average and total amount)
  - Figures 2, 3 and Annex Figures 1-9

**Outcome data**
- **15***
  - Report numbers of outcome events or summary measures over time
  - 8-16, Tables 1, 2 and Figures 2, 3 and Annex Tables 1, Annex Figures 1-9

**Main results**
- **16***
  - (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included
  - 6, Tables 1, 2 and Figures 2, 3 and Annex Figures 1-9
  - (b) Report category boundaries when continuous variables were categorized
  - Tables 1, 2 and Figures 2, 3 and Annex Table 1, Annex Figures 1-9
  - (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
  - N/A

**Other analyses**
- **17***
  - Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses
  - Tables 1, 2 and Figures 2, 3 and Annex Table 1, Annex Figures 1-9

### Discussion
<table>
<thead>
<tr>
<th>Key results</th>
<th>18</th>
<th>Summarize key results with reference to study objectives</th>
<th>17-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Limitations</td>
<td>19</td>
<td>Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias</td>
<td>18-19</td>
</tr>
<tr>
<td>Interpretation</td>
<td>20</td>
<td>Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence</td>
<td>17-19</td>
</tr>
<tr>
<td>Generalizability</td>
<td>21</td>
<td>Discuss the generalizability (external validity) of the study results</td>
<td>17-19</td>
</tr>
</tbody>
</table>

### Other information

| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 2, 20 |

*Give information separately for exposed and unexposed groups.*